LUNGLIFE AI INC. DL-0001
LungLife AI, Inc., a diagnostic company, researches and develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology in the United States and the People's Republic of China. The company engages in developing LungLB, a blood-based test to stratify cancerous and benign lung nodules identified by CT scan. The company was formerly known as Cynvenio Biosystems, I… Read more
LUNGLIFE AI INC. DL-0001 (9H4) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LUNGLIFE AI INC. DL-0001 (9H4) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LUNGLIFE AI INC. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how LUNGLIFE AI INC. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LUNGLIFE AI INC. DL-0001 (None–None)
The table below shows the annual net assets of LUNGLIFE AI INC. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LUNGLIFE AI INC. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LUNGLIFE AI INC. DL-0001 Competitors by Market Cap
The table below lists competitors of LUNGLIFE AI INC. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NSAV Holding Inc
PINK:NSAV
|
$355.96K |
|
MATADOR RES
BE:7MR
|
$356.00K |
|
Intema Solutions Inc
OTCQB:ITMZF
|
$356.12K |
|
NIPPON MEAT PACKERS - Dusseldorf Stock Exchang
DU:NI6
|
$356.25K |
|
KROPZ PLC LS-001
F:67W
|
$355.67K |
|
PIRAEUS PORT AUTH. NAM.
F:PZE
|
$355.58K |
|
MCX Technologies Corp
V:MCX
|
$355.55K |
|
Samlip General Foods Co. Ltd.
KQ:005610
|
$355.51K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LUNGLIFE AI INC. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LUNGLIFE AI INC. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LUNGLIFE AI INC. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LUNGLIFE AI INC. DL-0001's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $10,792,710,184
- Average return on equity (ROE) among peers: -33.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LUNGLIFE AI INC. DL-0001 (9H4) | €- | N/A | N/A | $355.70K |
| Spermosens AB (publ) (9R5) | $23.64 Million | -27.17% | 0.09x | $517.28K |
| BML Inc (BMZ) | $81.13 Billion | 8.19% | 0.43x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $3.07 Million | -162.85% | 1.21x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.43 Billion |
| Adicon Holdings Limited (K0U) | $1.77 Billion | 2.65% | 1.64x | $138.53 Million |
| WuXi XDC Cayman Inc. (L74) | $1.48 Billion | 10.52% | 0.69x | $2.11 Billion |
| NanoRepro AG (NN6) | $57.61 Million | 51.59% | 0.37x | $16.84 Million |
| PERRIGO (PGO) | $24.67 Million | -167.93% | 0.99x | $6.37K |